TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Google Secures Pentagon AI Deal for Classified Projects 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
WALTHAM, Mass., April 26, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in a fireside chat at the 42nd Annual Deutsche Bank Health Care Conference on Wednesday, May 3, 2017 at 2:50 p.m. ET.
A live audio webcast will be accessible through the Investors section of the company’s website at www.amagpharma.com, and will be archived for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. and CBR® is a registered trademark of CBR Systems, Inc.
AMAG Pharmaceuticals Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638
